Showing 1,581 - 1,600 results of 101,245 for search '(( 5 ((nn decrease) OR (a decrease)) ) OR ( 5 ((fold decrease) OR (mean decrease)) ))', query time: 1.60s Refine Results
  1. 1581
  2. 1582

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  3. 1583
  4. 1584

    Effects of T5-1 and T5-12 on TAS2R5 expression during protein synthesis inhibition. by Donghwa Kim (252081)

    Published 2025
    “…In the presence of CHX, T5-1 caused a decrease in receptor expression with the prolonged exposure, while T5-12 exposure had no significant effect on expression. * , P < 0.01 vs vehicle control.…”
  5. 1585
  6. 1586
  7. 1587
  8. 1588
  9. 1589
  10. 1590
  11. 1591
  12. 1592
  13. 1593
  14. 1594
  15. 1595
  16. 1596
  17. 1597
  18. 1598
  19. 1599
  20. 1600